Spirulina Tablets Treat Liver Fibrosis/Cirrhosis
Key facts
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 10 people, planned
- Started
- 26 Dec 2024
- Expected to end
- 26 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Spirulina tablet
- Maltodextrin (Placebo)
- Record updated
- 13 January 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Diagnosed with liver fibrosis or cirrhosis
- Patients scheduled for liver transplantation with a waiting time of more than 3 weeks
- Adults aged 18 to 75 years
- Willing to participate in the study and sign an informed consent form
- No acute diseases or significant exacerbation of symptoms in the 4 weeks prior to enrollment
Who cannot take part
- Patients allergic to Spirulina tablets
- Patients with a history of severe mental illness that could affect treatment adherence
- Patients with severe comorbidities
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Spirulina (Spirulina platensis, SP) is a nutrient-rich blue-green algae that has been widely studied and applied in various health fields. Its main components include spirulina polysaccharide proteins, amino acids, vitamins, and minerals, especially the eight essential amino acids that the human body cannot synthesize on its own. Spirulina is also rich in minerals such as iron, calcium, and zinc, which makes it beneficial in the prevention and treatment of several diseases. Research has shown that spirulina has potential therapeutic effects in combating tumors, obesity, diabetes, cardiovascular diseases, and anemia. In 2020, the National Health Commission of the People's Republic of China classified it as a health food supplement.
Read full original descriptionShow less
Hepatic fibrosis (HF) is a process of chronic liver disease caused by excessive repair responses to liver tissue injury due to various factors. As the fibrosis progresses, extracellular matrix in the liver accumulates, forming scar tissue that gradually replaces the normal liver parenchyma. Eventually, these pathological changes can lead to cirrhosis, portal hypertension, and even primary hepatocellular carcinoma (HCC), which may result in liver failure. Therefore, hepatic fibrosis is considered a critical precursor to cirrhosis and liver cancer.
In 2007, Elsharkawy and colleagues proposed the "hepatitis-fibrosis-liver cancer axis" theory, which emphasized that timely treatment of hepatic fibrosis is crucial to controlling the development of cirrhosis and liver cancer. However, modern medicine has yet to discover specific drugs for treating hepatic fibrosis or cirrhosis. The etiology of hepatic fibrosis is complex, involving various cellular and molecular mechanisms, thus making the in-depth study of its pathogenesis and the development of new treatments particularly urgent.
As the understanding of hepatic fibrosis continues to deepen, increasing attention is being given to the potential of natural products or health supplements in preventing and treating hepatic fibrosis. Spirulina, as a natural product with multiple biological activities, may become a promising direction for exploring new treatments for hepatic fibrosis due to its immune-regulating, antioxidant, and anti-inflammatory effects. Through further clinical and experimental research, spirulina may offer a new complementary treatment option for hepatic fibrosis.
The 2 groups in the trial
- placeboPlacebo, for comparison
The control group will receive an equivalent dose of maltodextrin for at least 3 weeks.
Treatment: Maltodextrin (Placebo)
- Spirulina treatmentExisting treatment, for comparison
In the Spirulina tablet intervention group, patients will receive oral Spirulina tablet treatment (2g/day) for at least 3 weeks before liver transplantation.
Treatment: Spirulina tablet
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Research on the Prevention and Treatment of Liver Fibrosis/Cirrhosis with Spirulina Tablets and Its Mechanisms
- Record updated
- 13 January 2025